Age-Related Macular Degeneration (Amd) Therapeutics Market - Global Analysis and Industry Forecast, 2013 - 2019

Submitted by: Submitted by

Views: 89

Words: 694

Pages: 3

Category: Business and Industry

Date Submitted: 07/10/2014 05:52 AM

Report This Essay

Macular degenerationtherapeutics are used to treat age-related macular degeneration (AMD), a chronic eye disease mostly observed in patient above the age of 50 years.AMD is more prevalent in developed nations and accounts for 8.7 percent of blindness in the world. AMD involves damage to macular areas which impairs the vision of an individual in the center of the retina. Age-related macular degeneration is of two kinds – wet macular degeneration and dry macular degeneration.The former type of AMD is more severe and involves abnormal growth of blood vessels in the macular area damaging the retinal vision. The market for macular degeneration therapeutics is driven by the number of AMD patients across the globe.According to American Academy of Ophthalmology, estimated 11 million Americans are affected by age related macular degeneration and the prevalence is large in countries among sub-Saharan Africa and South East Asia due vitamin A deficiency (VAD).

Read More @ http://www.transparencymarketresearch.com/amd-therapeutics.html

Currently there is no treatment available for common dry AMD, however therapies exist which can retard progression of wet AMD and visual impairment. These therapies include anti-vascular endothelial growth factor vaccines (anti-VEGF or angiogenic medicines), photodynamic therapy, photocoagulation and vitamin supplements (AREDS). The anti-VEGF medicines include ranibizumab, pegaptanib, aflibercept and bevacizumab. The photodynamic therapy uses verteporfin injection is used to destroy abnormal growth of blood vessels which halts the growth of AMD. The multivitamin therapy is suggested by National Eye Institute, of the U.S. National Institutes of Health for age-related macular degeneration. I-Caps (Alcon, Inc.) and PreserVision (Bausch &Lomb, Inc.) are the two available marketed preparations for AMD made using the AREDS formula.

Geographically, the global macular degeneration therapeutics market is segmented into four major regions, namely,...